Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference.
IPI-549 is an investigational oral immuno-oncology drug designed to treat advanced solid tumours by selectively inhibiting phosphoinositide-3-kinase-gamma (PI3K-gamma).
Go deeper with GlobalData
The data from preclinical study indicated that IPI-549 effects the myeloid cells and remodels the immune-suppressive tumour microenvironment, resulting in elimination of the resistance to immune checkpoint blockade.
The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy.
The Phase I study involves the evaluation of IPI-549 as a monotherapy and in combination with a PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumours.
Infinity Pharmaceuticals biology and translational science vice-president Jeffery Kutok said: "The data presented suggest that targeting PI3K-gamma by IPI-549 within immune-suppressive myeloid cells in the tumour microenvironment could offer a unique way to both enhance the activity of checkpoint inhibition in sensitive tumours, as well as to overcome tumour resistance to checkpoint inhibition.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Infinity is excited to be at the forefront of developing a potentially transformative approach within immuno-oncology, and we look forward to reporting additional data from our Phase I study of IPI-549 later this year."
The firm intends to further base its Phase I study in patients with non-small-cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN), on the data from the preclinical study.
